Malignant hyperthermia, susceptibility to, 4

Summary

Malignant hyperthermia, susceptibility to, 4 (MONDO:0010893) is a disease. A subtype of malignant hyperthermia, susceptibility to — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	malignant hyperthermia, susceptibility to, 4
Mondo ID	MONDO:0010893
MeSH	C535697
OMIM	600467
UMLS	C1838102
MedGen	324944
Is cancer (heuristic)	no

Also known as: malignant hyperpyrexia susceptibility type 4 · malignant hyperthermia susceptibility 4 · malignant hyperthermia susceptibility type 4 · malignant hyperthermia, susceptibility to, 4 · malignant hyperthermia, susceptibility to, type 4 · MHS4

Disease family

This is a subtype of malignant hyperthermia, susceptibility to. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease susceptibility › inherited disease susceptibility › malignant hyperthermia, susceptibility to › malignant hyperthermia, susceptibility to, 4

Related subtypes (5): malignant hyperthermia, susceptibility to, 1, malignant hyperthermia, susceptibility to, 2, malignant hyperthermia, susceptibility to, 3, malignant hyperthermia, susceptibility to, 5, malignant hyperthermia, susceptibility to, 6

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.